Carlo Russo
Chief Tech/Sci/R&D Officer bij GENENTA SCIENCE S.P.A.
Vermogen: 2 M $ op 31-03-2024
Actieve functies van Carlo Russo
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| GENENTA SCIENCE S.P.A. | Chief Tech/Sci/R&D Officer | 01-01-2021 | - |
Loopbaan van Carlo Russo
Eerdere bekende functies van Carlo Russo
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Chief Tech/Sci/R&D Officer | 18-05-2016 | 01-07-2016 |
VaxInnate Corp.
 VaxInnate Corp. Pharmaceuticals: MajorHealth Technology VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ. | Chief Executive Officer | - | - |
| President | - | - |
Opleiding van Carlo Russo
| University of Genoa | Doctorate Degree |
Statistieken
Internationaal
| Italië | 3 |
| Verenigde Staten | 3 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Chief Executive Officer | 1 |
| President | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| GENENTA SCIENCE S.P.A. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
VaxInnate Corp.
VaxInnate Corp. Pharmaceuticals: MajorHealth Technology VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ. | Health Technology |
- Beurs
- Insiders
- Carlo Russo
- Ervaring
